December 16, 2020
1 min watch
Save
VIDEO: CONTESSA trial oral chemo options for breast cancer patients
A phase 3 clinical trial, CONTESSA, investigated the treatment of HER2-negative, HR-positive metastatic breast cancer in patients who previously received taxane, and results were presented at this year’s San Antonio Breast Cancer Symposium.
According to Nancy U. Lin, MD, the trial compared tesetaxel plus a reduced dose of capecitabine with capecitabine alone.
“It really would provide a new oral chemotherapy for patients which I think is something that people really want,” Lin, an associate professor at Harvard Medical School and clinical director of the Breast Oncology Center at Dana-Farber Cancer Institute, said
Published by:
Sources/Disclosures
Collapse
Source:
O'Shaughnessy J, et al. Abstract GS4-01. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
O'Shaughnessy J, et al. Abstract GS4-01. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
Disclosures:
Lin reports serving as a consultant with AstraZeneca and receiving grant support from Genentech and Seattle Genetics.